INNOVATsIONNAYa SAKhAROSNIZhAYuShchAYa TERAPIYa: NOVAYa STRATEGIYa DLYa STAROY PROBLEMY


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper is devoted to the innovative strategy for the glucose-lowering therapy with using DPP-4 inhibitors. From the position of the evidence medicine the glycemic and non-glycemic effects, the efficacy, safety, the pathogenic aspects and clinical perspectives are wrote by sitagliptin, the first and the most distinguished representative of the incretins.

全文:

受限制的访问

参考

  1. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60(4):470-512.
  2. Анциферов МБ, Аметов АС, Зилов АВ. Ингибиторы ДПП-4: сегодня и завтра. Чего мы ждем от инкретинстимулирующей терапии?// Фарматека 2012. № 7. С. 81-6.
  3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55(6):1577-96.
  4. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.Diabetes Obes Metab 2010;12(5):442-51.
  5. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30(8):1979-87.
  6. Williams-Herman D, Xu L, Teng R, et al. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2012;14(1):67-76.
  7. Derosa G, Carbone A, D'Angelo A, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 2012;13(17):2433-42.
  8. Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonyl-ureas: a primary care database analysis. Diabetes Obes Metab 2013;15(1):55-61.
  9. Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann intern Med 2012;157(9):601-10.
  10. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97(12):4605-12.
  11. Currie CJ, Poole CD, Evans M, et al. Mortality and Other important Diabetes-Related Outcomes With insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. Clin Endocrinol Metab 2013;98(2):668-77.
  12. Pantalone KM, Kattan MW, Yu C, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010;33(6):1224-29.
  13. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13(2):160-68.
  14. Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. int J Clin Pract 2010;64(5):562-76.
  15. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9(2):194-205.
  16. Vora J, Bain SC, Damci T, et al. incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2012.pii: S1262-3636(12)00120-6.
  17. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSi study. Diabetes Obes Metab 2012;14(9):795-802.
  18. Yanai H, Adachi H, Hamasaki H, et al. Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res 2012;4(4):251-58.
  19. Aschner P, Chan J, Owens DR, et al. insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASiE): a multicentre, randomised open-label trial. Lancet 2012;379(9833):2262-69.
  20. Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. European Heart Journal Supplements 2012;14(Suppl. B):4-13.
  21. Ravassa S, Zudaire A, Dez J. Glucagon-like peptide 1 and cardiac cell survival. Endocrinol Nutr 2012;59(9):561-69.
  22. Shannon RP, Angeli FC. Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates. European Heart Journal 2012;14(Suppl. B):14-21.
  23. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7.
  24. Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12(1):3.
  25. Theiss HD, Brenner C, Engelmann MG, et al. Safety and efficacy of Sitagliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial infarction (SiTAGRAMi-Trial) - rationale, design and first interim analysis. int J Cardiol 2010;145(2):282-84.
  26. Poitout V. Lipotoxicity impairs incretin signalling. Diabetologia 2013;56(2):231-33.
  27. Derosa G, Ragonesi PD, Arrigo EF. Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. Fund Clin Pharm 2012;doi:1 0.1111/fcp.12001. [Accepted 03-Sep-2012].
  28. Кособян Е.П., Смирнова О.М. Современные концепции патогенеза неалкогольной жировой болезни печени // Сахарный диабет 2010. № 1. C. 55-65.
  29. iwasaki T, Yoneda M, inamori M, et al. Sitagliptin as a novel treatment agent for non alcoholic Fatty liver disease patients with type diabetes mellitus. Hepatogastroenterology 2011;58(112):2103-105.
  30. iwasaki T, Tomeno W, Yoneda M, et al. Nonalcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin. Hepatogastroenterology 2012;59( 11 7): 1522-25.
  31. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. int J Clin Pract 2010;64(7):984-90.
  32. Ferreira AJC, Marre M, Barzilai N, et al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderateto-Severe Chronic Renal insufficiency. Diabetes Care 2012 Dec 17.[Epub ahead of print].
  33. Chan JC, Scott R, Ferreira AJC, et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10(7):545-55.
  34. Ferreira AJC, Corry D, Mogensen CE, et al. Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial. Am J Kidney Dis 2013 Jan. doi: 10.1053/j.ajkd.2012.11.043. [Epub ahead of print].
  35. Kissow H, Hartmann B, Holst JJ. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept 2012;179(1-3):91-100.
  36. Mudaliar S, Henry RR. The incretin hormones: from scientific discovery to practical therapeutics. Diabetologia 2012;55(7):1865-68.
  37. Maiztegui B, Borelli Mi, Madrid VG, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased -cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011;120(2):73-80.
  38. Yeom JA, Kim ES, Park HS, et al. Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice. BMB Rep 2011;44(11):713-18.
  39. Шестакова М.В. Опыт применения ситаглиптина (первого ингибитора ДПП-4) в лечении сахарного диабета 2 типа в Российской Федерации: результаты наблюдательной программы "Диа-Да" // Сахарный диабет 2010. № 3. C. 57-60.
  40. Аметов А.С., Пакус Е.Н. Эффективность и безопасность комбинации метформина и ситаглиптина в лечении больных сахарным диабетом 2 типа с ожирением // Сахарный диабет 2010. № 3. C. 62-5.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##